BioNTech SE - ADR vs Newegg Commerce Inc — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Newegg Commerce Inc trades at $19.76 (market cap $398.29M). The key difference: BioNTech SE - ADR is far larger — about 58.5× Newegg Commerce Inc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| BNTX | NEGG | |
|---|---|---|
Market Cap | $23.31B | $398.29M |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $128.09 |
52-Week Low | $83.89 | $12.87 |
Enterprise Value | $6.60B | $397.09M |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Newegg Commerce (NEGG) trades at $19.80, up 7.73% with bullish technical signals and strong recent earnings beats. The stock shows improving fundamentals with revenue stabilizing around $1.4B and net income turning positive in 2026 forecasts. Recent business developments include AI shopping enhancements and exclusive product launches driving growth potential.
Outlook remains cautiously optimistic with improving profitability but carries execution risks. The high P/E ratio of 73.16 suggests premium valuation requiring sustained growth. Key opportunities include technology sector recovery and AI initiatives, while risks involve competitive pressures and cash flow volatility.
Trailing returns across standard periods
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →